Same receptor, different personalities
Ipamorelin and GHRP-6 are both growth-hormone secretagogues that act on the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth-hormone release from the pituitary. In research characterizations they are often grouped together, but they are studied as distinct molecules with different selectivity. This guide compares how the literature describes them—not how to use them, which is outside the scope of an educational resource.
Selectivity is the headline difference
GHRP-6 is one of the earliest synthetic GH-releasing peptides and is characterized in the literature as a relatively non-selective ghrelin-receptor agonist: alongside GH release it is noted for stimulating appetite and for effects on prolactin and cortisol at higher exposures. Ipamorelin was developed later and is frequently described as a more selective secretagogue—studied for GH release with comparatively little reported effect on cortisol and prolactin in preclinical work. Selectivity is the property most often cited to distinguish the two.
Appetite and the ghrelin connection
Because GHRP-6 more strongly mirrors the appetite-stimulating action of endogenous ghrelin, hunger is one of its most commonly described characteristics in the research literature. Ipamorelin is generally reported to have a milder appetite signal. This distinction is the reason the two peptides are studied for different experimental questions even though they share a receptor.
Why they are often paired with a GHRH analog
In experimental designs, ghrelin-receptor secretagogues like these are frequently studied alongside a GHRH analog such as CJC-1295 or sermorelin, because the two mechanisms (GHRH and ghrelin pathways) are complementary at the pituitary. That pairing is a recurring theme in the secretagogue literature and is covered in our CJC-1295 vs ipamorelin and GH secretagogues guides.
Half-life and structural notes
Both are short peptides cleared over minutes to a small number of hours, which is why the literature describes pulsatile exposure rather than sustained levels. Ipamorelin is a pentapeptide; GHRP-6 is a hexapeptide. Neither is a GHRH analog—they act on a different receptor than sermorelin, tesamorelin, or CJC-1295, a distinction that is easy to blur but mechanistically important.
Regulatory and safety framing
Neither ipamorelin nor GHRP-6 is an approved drug for general human use in Canada; they are handled in research contexts. Nothing here is a protocol, dose, or endorsement, and human use of unauthorized peptides carries real regulatory and safety considerations. Consult qualified professionals and Health Canada guidance for anything beyond laboratory study.
FAQ
What is the main difference between ipamorelin and GHRP-6?+
Selectivity. GHRP-6 is characterized as a less selective ghrelin-receptor agonist with a stronger appetite signal and more reported cortisol/prolactin effect at higher exposures, while ipamorelin is described as a more selective GH secretagogue with a milder appetite effect in preclinical work.
Do they work on the same receptor?+
Yes—both act on the ghrelin receptor (GHS-R1a) to stimulate growth-hormone release. That is different from GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, which act on the GHRH receptor.
Why is GHRP-6 associated with hunger?+
Because it closely mimics the appetite-stimulating action of endogenous ghrelin. That appetite signal is one of the most commonly reported characteristics of GHRP-6 in the literature and is milder for ipamorelin.
Are these peptides approved for human use?+
No. Neither is an approved drug for general human use in Canada. This guide is educational and describes how the research literature compares the two molecules—not how to use them.